Circulating tumor DNA dynamics in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer assessed using an ultrasensitive tumor-informed assay
Background Circulating tumor DNA (ctDNA) in early breast cancer (EBC) is prognostic for distant relapses. The ctDNA dynamics in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative EBC, which is considered low-shedding, are challenging to track. We used an ultrasensitive assay to dete...